Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935967 | 0.91 | CYP3A4 (0.47) | CYP3A4CYP1A2OPRD1MEN1KMT2A | |
| SCHEMBL4575741 | 0.90 | CYP3A4 (0.61) | CYP3A4CYP1A2OPRD1MEN1KMT2A | |
| SCHEMBL7093363 | 0.90 | CYP3A4 (0.61) | CYP3A4CYP1A2OPRD1MEN1KMT2A | |
| SCHEMBL4575871 | 0.88 | CYP3A4 (0.78) | CYP3A4CYP1A2OPRD1MEN1KMT2A | |
| SCHEMBL4575863 | 0.84 | CYP1A2 (0.59) | CYP3A4CYP1A2OPRD1OPRM1OPRK1 | |
| SCHEMBL4575592 | 0.84 | CYP1A2 (0.59) | CYP3A4CYP1A2OPRD1OPRM1OPRK1 | |
| SCHEMBL4576061 | 0.80 | OPRD1 (0.58) | CYP3A4CYP1A2OPRD1MEN1KMT2A | |
| SCHEMBL8069321 | 0.79 | OPRD1 (0.53) | CYP3A4CYP1A2OPRD1MEN1KMT2A | |
| SCHEMBL8069179 | 0.79 | OPRD1 (0.53) | CYP3A4CYP1A2OPRD1MEN1KMT2A | |
| SCHEMBL6935970 | 0.79 | CYP3A4 (0.63) | CYP3A4CYP1A2OPRD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296707-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-8865721-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575169-B2 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8551998-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | ENTA HOLDING LLC | 2008-08-14 | — | — | US | disclosed |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-6919350-B2 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-5807858-A | DIARYLMETHYLPIPERAZINE AND PIPERIDINE COMPOUNDS; SIDE EFFECTREDUCTION OF ANALGESICS | DELTA PHARMACEUTICAL, INC. (US) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP3A4 675/4885CYP1A2 760/4885OPRD1 1/4885 |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP3A4 675/4885CYP1A2 760/4885OPRD1 1/4885 |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP3A4 866/4885CYP1A2 751/4885OPRD1 1/4885 |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP3A4 675/4885CYP1A2 760/4885OPRD1 1/4885 |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP3A4 675/4885CYP1A2 760/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.